Virucide

SpectrumX Announces Lab Data Showing Its Spectricept™ Product Neutralises C. difficile Spores Within Minutes

Retrieved on: 
Thursday, October 13, 2022
Biotechnology, General Health, Pharmaceutical, Health, NHS, Health, Virucide, Virus, Infection, Patient, Hospital, Fungus, Clostridioides difficile infection, Temperature, Hypochlorous acid, Spore, Diarrhea, Patent, Bacteria, Public Health England, Human, Pharmaceutical industry, Vaccine

SpectrumX, a UK-based healthcare and pharmaceutical company, today announces that following successful lab testing, the proprietary, skin-safe formulation of hypochlorous acid (HOCl) contained in the Companys Spectricept product has efficacy in neutralising a wide range of pathogens, including Clostridium difficile spores (C. diff).

Key Points: 
  • SpectrumX, a UK-based healthcare and pharmaceutical company, today announces that following successful lab testing, the proprietary, skin-safe formulation of hypochlorous acid (HOCl) contained in the Companys Spectricept product has efficacy in neutralising a wide range of pathogens, including Clostridium difficile spores (C. diff).
  • C. diff spores are often found in health care facilities and hospitals, and the arising bacterium can infect the bowel, causing diarrhoea and other serious health effects.
  • The tests investigated the efficacy of SpectrumX sanitising mist, which is composed of the same patent-pending formulation as the Companys hand sanitiser, on various bacteria and viruses.
  • The formulation met or exceeded both the sporicidal and virucidal standards EN14476 and EN17126, respectively to eliminate multiple spores and viruses.

VIRALEZE SPL7013 virucidal (>99.99%) against Delta variant

Retrieved on: 
Tuesday, July 27, 2021
Coronaviridae, Sarbecovirus, Zoonoses, Biocides, Severe acute respiratory syndrome coronavirus 2, Variants of SARS-CoV-2, Antiviral drug, Virucide, COVID-19, Coronavirus, Severe acute respiratory syndrome, GC376

New antiviral testing demonstrates SPL7013, the antiviral agent in VIRALEZE nasal spray, has potent virucidal activity against the globally significant Delta variant of SARS-CoV-2, reducing infectivity of the virus by >99.99% after 30 seconds of exposure

Key Points: 
  • New antiviral testing demonstrates SPL7013, the antiviral agent in VIRALEZE nasal spray, has potent virucidal activity against the globally significant Delta variant of SARS-CoV-2, reducing infectivity of the virus by >99.99% after 30 seconds of exposure
    SPL7013, the antiviral agent in VIRALEZE, has now been shown in laboratory studies to be virucidal against all four coronavirus SARS-CoV-2 Variants of Concern: Alpha, Beta, Gamma and Delta
    These latest data further illustrate the broad-spectrum antiviral activity of SPL7013, which has been demonstrated against multiple respiratory viruses, including influenza and RSV, as well as its consistent and potent activity against multiple SARS-CoV-2 variants
    VIRALEZE antiviral nasal spray is registered for sale in Europe and India, and available in certain markets online.
  • MELBOURNE, Australia, July 27, 2021 /PRNewswire/-- Starpharma today announced new data demonstrating that SPL7013, the antiviral agent in VIRALEZE nasal spray, is active against the highly transmissible Delta variant of SARS-CoV-2, achieving more than 99.99% reduction of infectious virus in laboratory-based virucidal assays.
  • The antiviral testing of SPL7013 was conducted in the laboratory of virologist, Professor Philippe Gallay, atThe Scripps Research Institute in the US, where previous studies have also demonstrated potent antiviral and virucidal activity of SPL7013 against multiple variants of SARS-CoV-2, including the globally important Alpha, Beta and Gamma 'Variants of Concern'.
  • Percent reductions of infectious virus achieved with 10 mg/mL SPL7013 (the concentration in VIRALEZE) are shown in the table below.

State® Industrial Products Introduces New 7 in One™ Disinfectant

Retrieved on: 
Tuesday, January 19, 2021
Hygiene, Biocides, Cleaning products, Bactericides, Disinfectant, Virucide, Air freshener, Medical specialties, Branches of biology, Chemical substances

7 in One Concentrate is State's newest concentrated quaternary disinfectant that acts as a seven-in-one cleaner, sanitizer, fungicide, mildewstat, virucide, deodorizer and bactericide.

Key Points: 
  • 7 in One Concentrate is State's newest concentrated quaternary disinfectant that acts as a seven-in-one cleaner, sanitizer, fungicide, mildewstat, virucide, deodorizer and bactericide.
  • State Industrial Products has helped customers "Care for Work Environments" since 1911.
  • From market-leading drain maintenance and air care programs to innovative cleaning systems, maintenance supplies and auxiliary programs, State Industrial Products offers facility management benefits that are second to none.
  • For more information on State Industrial Products, visit stateindustrial.com or call 866-747-2229.

Grignard Company Seeks Federal and State Government Approvals on Atmospheric Haze Product Expected to Inactivate Coronavirus

Retrieved on: 
Wednesday, April 29, 2020
Manufacturing, Infectious diseases, Environment, Health, Chemicals, Plastics, Physical sciences, Chemistry, Natural sciences, Chemical elements, Dietary minerals, Grignard, Virucide, Iodine, Viral envelope

Grignard Company, a manufacturer of atmospheric effect solutions, announces that it is seeking approval from federal and state agencies for its Grignard Pure product as an atmospheric viricide.

Key Points: 
  • Grignard Company, a manufacturer of atmospheric effect solutions, announces that it is seeking approval from federal and state agencies for its Grignard Pure product as an atmospheric viricide.
  • Grignard Pure creates a light atmospheric haze throughout an indoor space that inactivates enveloped viruses such as the novel coronavirus on non-porous hard surfaces and in the air -- where it is most dangerous.
  • Grignard Company expects favorable rulings from all agencies within the coming days.
  • It gives guidance to state and local governments on how they can execute a phased way to support safe reopening.

Ecolab’s OxyCide™ Daily Disinfectant Cleaner Receives U.S. EPA Candida Auris Claim

Retrieved on: 
Thursday, October 24, 2019
Other Manufacturing, Medical Supplies, Infectious diseases, Hospitals, Chemicals, Plastics, Manufacturing, Practice Management, Other Health, General Health, Health, Biocides, Biology, Health, Public health, Bactericides, Disinfectant, Virucide, Hygiene, Antimicrobial, Reckitt Benckiser, Candida auris

Ecolab Inc., the global leader in water, hygiene and energy technologies and services that protect people and vital resources, has received U.S. Environmental Protection Agency (EPA) approval for its OxyCide Daily Disinfectant Cleaner for efficacy against Candida auris (C. auris), an emerging fungal pathogen that presents a serious global health threat.

Key Points: 
  • Ecolab Inc., the global leader in water, hygiene and energy technologies and services that protect people and vital resources, has received U.S. Environmental Protection Agency (EPA) approval for its OxyCide Daily Disinfectant Cleaner for efficacy against Candida auris (C. auris), an emerging fungal pathogen that presents a serious global health threat.
  • OxyCide Daily Disinfectant Cleaner is an EPA-registered one-step disinfectant cleaner, virucide and deodorizer with sporicidal activity designed for daily hospital use on both flexible and hard non-porous surfaces.
  • Designed for daily, discharge and isolation cleaning, OxyCide Daily Disinfectant Cleaner enables product standardization and workflow simplification by replacing multiple products with one solution.
  • The OxyCide Daily Disinfectant Cleaner claim against C. auris is currently being reviewed by state agencies, including the California Department of Pesticide Regulation (CDPR).